Natixis Advisors LLC Grows Stock Holdings in Haleon plc (NYSE:HLN)

Natixis Advisors LLC grew its position in shares of Haleon plc (NYSE:HLN) by 3.6% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,527,392 shares of the company’s stock after buying an additional 53,625 shares during the quarter. Natixis Advisors LLC’s holdings in Haleon were worth $14,571,000 as of its most recent filing with the SEC.

Several other large investors have also recently added to or reduced their stakes in HLN. Sierra Ocean LLC purchased a new position in Haleon in the fourth quarter valued at about $26,000. Versant Capital Management Inc raised its position in shares of Haleon by 2,029.1% in the fourth quarter. Versant Capital Management Inc now owns 3,513 shares of the company’s stock valued at $34,000 after buying an additional 3,348 shares during the last quarter. Geneos Wealth Management Inc. purchased a new position in shares of Haleon during the fourth quarter valued at approximately $35,000. Toronto Dominion Bank boosted its holdings in shares of Haleon by 3,470.0% during the third quarter. Toronto Dominion Bank now owns 3,570 shares of the company’s stock worth $38,000 after purchasing an additional 3,470 shares during the last quarter. Finally, Spire Wealth Management acquired a new stake in shares of Haleon in the fourth quarter worth approximately $39,000. 6.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

HLN has been the subject of several research reports. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Haleon in a research note on Monday, March 3rd. Sanford C. Bernstein lowered Haleon from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 8th. Morgan Stanley cut shares of Haleon from an “overweight” rating to an “equal weight” rating in a research report on Friday, January 10th. Hsbc Global Res lowered shares of Haleon from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, March 5th. Finally, HSBC reaffirmed a “hold” rating on shares of Haleon in a report on Wednesday, March 5th. Six research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $10.95.

Haleon Stock Performance

HLN opened at $10.38 on Thursday. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. The business’s 50 day moving average is $9.80 and its 200-day moving average is $9.88. The stock has a market cap of $46.97 billion, a PE ratio of 30.51, a price-to-earnings-growth ratio of 2.82 and a beta of 0.25. Haleon plc has a twelve month low of $7.99 and a twelve month high of $10.80.

Haleon (NYSE:HLN) last released its quarterly earnings results on Thursday, February 27th. The company reported $0.05 EPS for the quarter. Haleon had a net margin of 10.85% and a return on equity of 14.76%. The company had revenue of $3.54 billion for the quarter, compared to the consensus estimate of $3.38 billion. On average, analysts predict that Haleon plc will post 0.43 earnings per share for the current year.

Haleon Increases Dividend

The business also recently declared a — dividend, which will be paid on Thursday, June 5th. Investors of record on Friday, April 25th will be paid a $0.1166 dividend. The ex-dividend date is Friday, April 25th. This represents a yield of 1.6%. This is a boost from Haleon’s previous — dividend of $0.05. Haleon’s dividend payout ratio (DPR) is currently 58.97%.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.